These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30153853)

  • 1. Biochemical and pathological changes result from mutated Caveolin-3 in muscle.
    González Coraspe JA; Weis J; Anderson ME; Münchberg U; Lorenz K; Buchkremer S; Carr S; Zahedi RP; Brauers E; Michels H; Sunada Y; Lochmüller H; Campbell KP; Freier E; Hathazi D; Roos A
    Skelet Muscle; 2018 Aug; 8(1):28. PubMed ID: 30153853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caveolin-3 deficiency associated with the dystrophy P104L mutation impairs skeletal muscle mitochondrial form and function.
    Shah DS; Nisr RB; Stretton C; Krasteva-Christ G; Hundal HS
    J Cachexia Sarcopenia Muscle; 2020 Jun; 11(3):838-858. PubMed ID: 32090499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The caveolin-3 P104L mutation in LGMD-1C patients inhibits non-insulin-stimulated glucose metabolism and growth but promotes myocyte proliferation.
    Shang L; Chen T; Xian J; Deng Y; Huang Y; Zhao Q; Liang G; Liang Z; Lian F; Wei H; Huang Q
    Cell Biol Int; 2019 Jun; 43(6):669-677. PubMed ID: 30958599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endoplasmic reticulum stress response in P104L mutant caveolin-3 transgenic mice.
    Kuga A; Ohsawa Y; Okada T; Kanda F; Kanagawa M; Toda T; Sunada Y
    Hum Mol Genet; 2011 Aug; 20(15):2975-83. PubMed ID: 21610159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular and muscle pathology in a series of caveolinopathy patients.
    Fulizio L; Nascimbeni AC; Fanin M; Piluso G; Politano L; Nigro V; Angelini C
    Hum Mutat; 2005 Jan; 25(1):82-9. PubMed ID: 15580566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the muscular dystrophy-associated caveolin-3(P104L) mutant in adult mouse skeletal muscle specifically alters the Ca(2+) channel function of the dihydropyridine receptor.
    Weiss N; Couchoux H; Legrand C; Berthier C; Allard B; Jacquemond V
    Pflugers Arch; 2008 Nov; 457(2):361-75. PubMed ID: 18509671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Caveolin-3 P104L mutation of LGMD-1C leads to disordered glucose metabolism in muscle cells.
    Deng YF; Huang YY; Lu WS; Huang YH; Xian J; Wei HQ; Huang Q
    Biochem Biophys Res Commun; 2017 Apr; 486(2):218-223. PubMed ID: 28232187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caveolin-3 is a direct molecular partner of the Cav1.1 subunit of the skeletal muscle L-type calcium channel.
    Couchoux H; Bichraoui H; Chouabe C; Altafaj X; Bonvallet R; Allard B; Ronjat M; Berthier C
    Int J Biochem Cell Biol; 2011 May; 43(5):713-20. PubMed ID: 21262376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Caveolin-3 G56S sequence variant of unknown significance: Muscle biopsy findings and functional cell biological analysis.
    Brauers E; Roos A; Kollipara L; Zahedi RP; Beckmann A; Mohanadas N; Bauer H; Häusler M; Thoma S; Kress W; Senderek J; Weis J
    Proteomics Clin Appl; 2017 Jan; 11(1-2):. PubMed ID: 27739254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Membrane repair defects in muscular dystrophy are linked to altered interaction between MG53, caveolin-3, and dysferlin.
    Cai C; Weisleder N; Ko JK; Komazaki S; Sunada Y; Nishi M; Takeshima H; Ma J
    J Biol Chem; 2009 Jun; 284(23):15894-902. PubMed ID: 19380584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caveolin-3 loss linked with the P104L LGMD-1C mutation modulates skeletal muscle mTORC1 signalling and cholesterol homeostasis.
    Shah DS; Nisr RB; Krasteva-Christ G; Hundal HS
    J Cachexia Sarcopenia Muscle; 2023 Oct; 14(5):2310-2326. PubMed ID: 37671684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caveolinopathies: mutations in caveolin-3 cause four distinct autosomal dominant muscle diseases.
    Woodman SE; Sotgia F; Galbiati F; Minetti C; Lisanti MP
    Neurology; 2004 Feb; 62(4):538-43. PubMed ID: 14981167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caveolinopathies: from the biology of caveolin-3 to human diseases.
    Gazzerro E; Sotgia F; Bruno C; Lisanti MP; Minetti C
    Eur J Hum Genet; 2010 Feb; 18(2):137-45. PubMed ID: 19584897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sarcolemmal neuronal nitric oxide synthase defect in limb-girdle muscular dystrophy: an adverse modulating factor in the disease course?
    Fanin M; Tasca E; Nascimbeni AC; Angelini C
    J Neuropathol Exp Neurol; 2009 Apr; 68(4):383-90. PubMed ID: 19287313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of caveolin-3 induced by the dystrophy-associated P104L mutation impairs L-type calcium channel function in mouse skeletal muscle cells.
    Couchoux H; Allard B; Legrand C; Jacquemond V; Berthier C
    J Physiol; 2007 May; 580(Pt.3):745-54. PubMed ID: 17317753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunofluorescence-Based Analysis of Caveolin-3 in the Diagnostic Management of Neuromuscular Diseases.
    Roos A; Hathazi D; Schara U
    Methods Mol Biol; 2020; 2169():197-216. PubMed ID: 32548831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two novel CAV3 gene mutations in Japanese families.
    Sugie K; Murayama K; Noguchi S; Murakami N; Mochizuki M; Hayashi YK; Nonaka I; Nishino I
    Neuromuscul Disord; 2004 Dec; 14(12):810-4. PubMed ID: 15564037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caveolinopathies: translational implications of caveolin-3 in skeletal and cardiac muscle disorders.
    Gazzerro E; Bonetto A; Minetti C
    Handb Clin Neurol; 2011; 101():135-42. PubMed ID: 21496630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Muscular atrophy of caveolin-3-deficient mice is rescued by myostatin inhibition.
    Ohsawa Y; Hagiwara H; Nakatani M; Yasue A; Moriyama K; Murakami T; Tsuchida K; Noji S; Sunada Y
    J Clin Invest; 2006 Nov; 116(11):2924-34. PubMed ID: 17039257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAV3 mutations causing exercise intolerance, myalgia and rhabdomyolysis: Expanding the phenotypic spectrum of caveolinopathies.
    Scalco RS; Gardiner AR; Pitceathly RD; Hilton-Jones D; Schapira AH; Turner C; Parton M; Desikan M; Barresi R; Marsh J; Manzur AY; Childs AM; Feng L; Murphy E; Lamont PJ; Ravenscroft G; Wallefeld W; Davis MR; Laing NG; Holton JL; Fialho D; Bushby K; Hanna MG; Phadke R; Jungbluth H; Houlden H; Quinlivan R
    Neuromuscul Disord; 2016 Aug; 26(8):504-10. PubMed ID: 27312022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.